for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vir Biotechnology Inc

VIR.OQ

Latest Trade

52.75USD

Change

-0.12(-0.23%)

Volume

141,844

Today's Range

52.40

 - 

54.21

52 Week Range

11.67

 - 

74.80

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
52.87
Open
52.51
Volume
141,844
3M AVG Volume
30.96
Today's High
54.21
Today's Low
52.40
52 Week High
74.80
52 Week Low
11.67
Shares Out (MIL)
127.05
Market Cap (MIL)
6,556.88
Forward P/E
-20.62
Dividend (Yield %)
--

Latest Developments

More

Vir Biotechnology Reports Q2 Loss Per Share Of $0.27

Vir Biotechnology Announces Pricing Of Public Offering Of Common Stock

Vir Biotechnology Announces Proposed Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vir Biotechnology Inc

Vir Biotechnology, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments to treat and prevent serious infectious diseases. Its technology platforms are focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid (siRNA). Its pipeline consists of product candidates targeting hepatitis B virus (HBV), influenza A, human immunodeficiency virus (HIV) and tuberculosis (TB). Its product candidates include VIR-2218, VIR-3434, VIR-2482, VIR-1111 and VIR-2020. The Company is developing VIR-2218 and VIR-3434 for the functional cure of HBV. VIR-2218 is a subcutaneously administered HBV-targeting siRNA. VIR-3434 is a subcutaneously administered HBV-neutralizing monoclonal antibody (mAb). VIR-2482 is an intramuscularly administered influenza A-neutralizing mAb. VIR-1111 is a subcutaneously administered HIV T cell vaccine. VIR-2020 is a subcutaneously administered TB T cell vaccine.

Industry

Biotechnology & Drugs

Contact Info

499 Illinois St Ste 500

SAN FRANCISCO, CA

94158-2521

United States

+1.415.9064324

https://www.vir.bio/

Executive Leadership

Vicki L. Sato

Independent Chairman of the Board

George A. Scangos

President, Chief Executive Officer, Director

Jay Parrish

Chief Business Officer

Howard Horn

Chief Financial Officer, Secretary

Herbert Virgin

Executive Vice President of Research and Chief Scientific Officer

Key Stats

3.20 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020(E)

0.0K
EPS (USD)

2019

-5.760

2020(E)

-2.493
Price To Earnings (TTM)
--
Price To Sales (TTM)
87.32
Price To Book (MRQ)
11.00
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.19
LT Debt To Equity (MRQ)
0.14
Return on Investment (TTM)
-42.67
Return on Equity (TTM)
-39.06

Latest News

Latest News

Vir Biotech to begin mid-to-late stage study of COVID-19 drug candidate in August

Vir Biotechnology Inc said on Tuesday it plans to start a mid-to-late stage trial of its COVID-19 drug candidate in August, as drugmakers across the globe rush to find treatments for the highly infectious virus.

BRIEF-Vir Biotechnology Announces Pricing Of Public Offering Of Common Stock

* VIR BIOTECHNOLOGY ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Vir Biotechnology Announces Proposed Public Offering Of Common Stock

* VIR BIOTECHNOLOGY ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Vir Biotechnology - On June 15, Co & Wuxi Biologics Entered Into A Binding Letter Of Intent

* VIR BIOTECHNOLOGY - ON JUNE 15, CO & WUXI BIOLOGICS ENTERED INTO A BINDING LETTER OF INTENT

BRIEF-Vir Biotechnology And Biogen Execute Agreement To Manufacture Sars-Cov-2 Antibodies For Potential Covid-19 Treatment

* VIR BIOTECHNOLOGY AND BIOGEN EXECUTE AGREEMENT TO MANUFACTURE SARS-COV-2 ANTIBODIES FOR POTENTIAL COVID-19 TREATMENT

BRIEF-Vir Biotechnology Initiates Phase 1 Clinical Trial Of Vir-3434 For Chronic Hepatitis B Virus Infection

* VIR BIOTECHNOLOGY INITIATES PHASE 1 CLINICAL TRIAL OF VIR-3434 FOR CHRONIC HEPATITIS B VIRUS INFECTION Source text for Eikon: Further company coverage:

BRIEF-Vir Biotechnology Q1 Loss Per Share $0.71

* VIR BIOTECHNOLOGY PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

Vir, Alnylam plan human trials by year-end for potential COVID-19 therapy

Vir Biotechnology Inc and Alnylam Pharmaceuticals Inc plan to begin human testing of their COVID-19 drug candidate by the end of the year, as drugmakers across the globe scramble to find therapies for the highly-infectious virus.

Vir, Alnylam plan human trials by year-end for potential COVID-19 therapy

Vir Biotechnology Inc and Alnylam Pharmaceuticals Inc plan to begin human testing of their COVID-19 drug candidate by the end of the year, as drugmakers across the globe scramble to find therapies for the highly-infectious virus.

Vir, Alnylam pick coronavirus therapy candidate, plan human trials by year end

Vir Biotechnology Inc and Alnylam Pharmaceuticals Inc have identified a drug candidate for treating COVID-19 and plan to begin human testing by the end of the year, the companies said on Monday.

BRIEF-Vir Biotechnology Inc Reports Positive Data From Hepatitis B Phase 1/2 Trial

* VIR-2218 DEMONSTRATES DOSE-DEPENDENT AND DURABLE REDUCTIONS OF HEPATITIS B SURFACE ANTIGEN IN PHASE 1/2 TRIAL

GSK to partner with Vir for potential COVID-19 treatments, invest $250 million

British drugmaker GlaxoSmithKline will invest $250 million in Vir Biotechnology Inc and collaborate to develop potential antibody treatments for COVID-19, the disease caused by the new coronavirus, the companies said on Monday.

CORRECTED-UPDATE 1-GSK to partner with Vir for potential COVID-19 treatments, invest $250 mln

British drugmaker GlaxoSmithKline will invest $250 million in Vir Biotechnology Inc and collaborate to develop potential treatments for COVID-19, the disease caused by the new coronavirus, the companies said on Monday.

BRIEF-GSK To Collaborate With Vir Biotechnology For Potential COVID-19 Treatments, Invest $250 Mln

* GSK AND VIR BIOTECHNOLOGY ENTER COLLABORATION TO FIND CORONAVIRUS SOLUTIONS

GSK to partner with Vir for potential COVID-19 treatments, invest $250 mln

British drugmaker GlaxoSmithKline Plc will invest $250 million in Vir Biotechnology Inc and collaborate to develop potential treatments for COVID-19, the disease caused by the new coronavirus, the companies said on Monday.

BRIEF-Generation Bio And Vir Biotechnology To Collaborate On Research To Leverage Scalable Non-Viral Gene Therapy Platform

* GENERATION BIO AND VIR BIOTECHNOLOGY TO COLLABORATE ON RESEARCH TO LEVERAGE SCALABLE NON-VIRAL GENE THERAPY PLATFORM FOR DURABLE PRODUCTION OF MONOCLONAL ANTIBODIES AGAINST CORONAVIRUS THAT CAUSES COVID-19 Source text for Eikon: Further company coverage:

BRIEF-Vir Biotechnology Reports Q4 Revenue Of $1.0 Mln

* VIR BIOTECHNOLOGY PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Xencor And Vir Biotechnology Enter License Agreement For Use Of Xtend™ Xmab® Antibody Technology

* XENCOR AND VIR BIOTECHNOLOGY ENTER LICENSE AGREEMENT FOR USE OF XTEND™ XMAB® ANTIBODY TECHNOLOGY IN INVESTIGATIONAL ANTIBODIES TO TREAT COVID-19

BRIEF-Vir Biotechnology Proceeding With Two Clinical Development Candidates For COVID-19

* VIR BIOTECHNOLOGY PROCEEDING WITH TWO CLINICAL DEVELOPMENT CANDIDATES FOR COVID-19

BRIEF-Vir Biotechnology Announces Intent To Collaborate With Biogen On Manufacturing Of Antibodies To Potentially Treat Covid-19

* VIR BIOTECHNOLOGY ANNOUNCES INTENT TO COLLABORATE WITH BIOGEN ON MANUFACTURING OF ANTIBODIES TO POTENTIALLY TREAT COVID-19

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up